http://repository.usmf.md:80/xmlui/handle/20.500.12710/17976 2026-04-10T20:54:07Z 2026-04-10T20:54:07Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/17994 2021-12-21T12:02:15Z 2021-01-01T00:00:00Z

The Moldovan Medical Journal. September 2021, Vol. 64, No 3 The Moldovan Medical Journal is an international scientific double-blind peer-reviewed periodical edition, 4 per year, of the Scientific Medical Association of the Republic of Moldova designed for specialists in the areas of medicine, dentistry, pharmacy, social medicine, and public health. From its debut, the journal has striven to support the interests of Moldovan medicine concerning the new concepts of its development. The Editorial Board warmly welcomes both the readers of and the authors of the journal, all those who are enthusiastic about searching for new and more effective ways of solving numerous medical problems. We hope that those who want to make their contribution to the science of medicine will find our journal helpful and encouraging.

2021-01-01T00:00:00Z Ceban, Emil http://repository.usmf.md:80/xmlui/handle/20.500.12710/17993 2021-12-21T12:00:44Z 2021-01-01T00:00:00Z

Academician Eugen Gladun – on the 85th anniversary 27.04.1936–30.05.2014 Ceban, Emil

2021-01-01T00:00:00Z Belenciuc, Anna Bubuioc, Ana-Maria Odainic, Olesea Sangheli, Marina Gavriliuc, Mihail Lisnic, Vitalie http://repository.usmf.md:80/xmlui/handle/20.500.12710/17992 2021-12-21T11:59:01Z 2021-01-01T00:00:00Z

Pregnancy in multiple sclerosis: from scientific aspects to practical Belenciuc, Anna; Bubuioc, Ana-Maria; Odainic, Olesea; Sangheli, Marina; Gavriliuc, Mihail; Lisnic, Vitalie Background: Multiple sclerosis (MS) is a disease that affects young people of reproductive age (20-40 years old), predominantly women. Therefore, almost every patient has questions about pregnancy and breastfeeding. Family planning is one of the key issues in the choice of treatment tactics. Despite the growing number of therapeutic options for individualized treatment, it is still a question how to manage women with MS who become pregnant while taking disease-modifying drugs or want to become pregnant after starting this treatment. Conclusions: Women with MS should not be discouraged from pregnancy due to their illness. It is necessary to proactively discuss pregnancy planning with all women with MS of childbearing age. Based on available data, interferon beta and glatiramer acetate appear to be most suitable for use up until the time of confirmed pregnancy. A large amount of data (more than 1000 cases) obtained from registries shows that use of interferon beta before conception and during pregnancy suggests no evidence of increase in the rate of congenital anomalies or spontaneous abortions. For women with persistent high disease activity, pulsed immune reconstitution therapy gives additional opportunity for family planning after the last dose. The choice between available options for pulsed immune reconstitution therapy should be based on efficacy balanced against the risks.

2021-01-01T00:00:00Z Friptu, Valentin Mitriuc, Diana Popusoi, Olga http://repository.usmf.md:80/xmlui/handle/20.500.12710/17991 2021-12-21T11:56:15Z 2021-01-01T00:00:00Z

Hereditary thrombophilia and adverse pregnancy outcomes Friptu, Valentin; Mitriuc, Diana; Popusoi, Olga Background: Multiple studies have found a relatively increased risk of placenta-mediated pregnancy complications in women with congenital thrombophilia, especially early recurrent pregnancy loss, fetal loss, early-onset preeclampsia, intrauterine growth restriction, and premature abruption of normally positioned placenta. However, the extent of the association and the absolute risk are very modest, but they significantly increase in pregnant women with severe obstetric complications. Conclusions: There is convincing evidence that deficiency of natural anticoagulants (antithrombin, protein C, protein S) is a risk factor for late fetal loss. Factor V Leiden G1691A gene mutation and prothrombin G20210A gene mutation are associated with a double risk for early and unexplained recurrent pregnancy loss and for non-recurrent late fetal loss. The association of congenital thrombophilia with preeclampsia is much more uncertain, being probably limited factor V Leiden G1691A gene mutation and more severe cases of preeclampsia. Fewer data are available on intrauterine growth restriction (IUGR) and premature abruption of the normally positioned placenta. There is insufficient evidence to suggest an association of other forms of congenital thrombophilia with adverse pregnancy outcomes. In addition, genetic and epidemiological research suggests that placenta-mediated pregnancy complications are of polygenic multifactorial etiology, with a risk determined by the interaction of multiple genetic variants and other risk factors.

2021-01-01T00:00:00Z